EUCTR2015-003394-15-DE进行中（未招募）1 期
OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDER
Vanda Pharmaceuitcals Inc.0 个研究点目标入组 24 人开始时间: 2016年7月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent from parents having parental responsibility or from the legal guardian(s). In the case of a child is aged 12 years or older the written assent of the child is needed in addition to that of parents having responsibility/legal guardian;
- •2. Males or females between 3 to <18 years;
- •3. Children in cohort 1 (age 3 to < 6) must be daytime toilet trained;
- •4. Body Mass Index (BMI) within the 5th and 95th percentile based on age (BMI =
- •weight (kg)/ [height (m)]2);
- •5. Weigh at least 16 kg;
- •6. Post-pubescent girls already having menses must have a negative pregnancy test at the screening and baseline visits;
- •7. No perception of light and Diagnosis of Non-24-Hour Sleep-Wake Disorder as determined by:
- •a.History (within the last 3 months) of trouble sleeping at night (difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire, and
- •b. A non-entrained urinary aMT6s rhythm defined as a tau = 24.10 h and 95% confidence interval (CI) that does not include 24;
- •8. Willing and able to comply with study requirements and restrictions including a commitment to a fixed sleep opportunity during the study;
- •9. Subjects who fail to respond to behavior modification/sleep hygiene measures during the Pre-Enrollment Phase as determined by the physician through patient interview and/or sleep diaries
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 24
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have a probable diagnosis of a current sleep disorder other than Non-24-Hour Sleep-Wake Disorder that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;
- •2. History (within the 12 months prior to screening) of psychiatric disorders including ADHD, Autism, Neurodisabilities, Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder, that is not being successfully treated or has not been resolved and that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
- •3. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;
- •4. Subjects having any suicidal ideation of type 4 or 5 on the C-SSRS at Screening or Baseline;
- •5. Subject is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;
- •6. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
- •7. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening as determined by the clinical investigator;
- •8. Indication of impaired liver function (values for AST, ALT or bilirubin > 2 times
- •Upper Limit of Normal);
- •9. Pregnant or lactating females;
- •10. Smokers;
- •11. Exposure to any investigational drug, including placebo, within 30 days or 5 half- lives (whichever was longer) of screening;
- •12. Unwilling or unable to follow the medication restrictions described in Section 8.2, or unwilling or unable to sufficiently wash-out from use of a restricted medication;
- •13. Any other sound medical reason as determined by the clinical investigator
研究者
相似试验
进行中（未招募）
1 期
OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDERThis study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blind with no conscious light perception and exhibit/have Non-24-Hour Sleep-Wake DisorderMedDRA version: 19.0Level: PTClassification code 10040984Term: Sleep disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2015-003394-15-GBVanda Pharmaceuitcals Inc.24
进行中（未招募）
1 期
OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF TASIMELTEON IN TOTALLY BLIND CHILDREN AND ADOLESCENTS WITH NON-24-HOUR SLEEP- WAKE DISORDERThis study will be an open-label, single dose, non-controlled trial to evaluate the pharmacokinetics and safety of tasimelteon in children who are 3 years to less than 18 years of age, totally blind with no conscious light perception and exhibit/have Non-24-Hour Sleep-Wake DisorderMedDRA version: 19.1Level: PTClassification code 10040984Term: Sleep disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2015-003394-15-FRVanda Pharmaceuitcals Inc.24
进行中（未招募）
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: LLTClassification code 10054380Term: Familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-DEEsperion Therapeutics, Inc.54
招募中
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-NLEsperion Therapeutics, Inc.54
进行中（未招募）
1 期
A study to evaluate how much bempedoic acid is in the body, and the effects and safety of bempedoic acid in children (6 to 17 years of age) with heterozygous familial hypercholesterolemia (a type of high cholesterol) receiving once daily oral dosing.HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAEUCTR2018-004084-31-ESEsperion Therapeutics, Inc.54